SS Innovations International Inc. (NASDAQ: SSII) has demonstrated its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console in a series of remote operations, including a robotic-assisted cardiac procedure performed by a surgeon approximately 7,500 miles from the patient. The demonstrations, which took place at medical conferences in Spain and India in October 2026, underscore the growing potential of tele-surgery to extend specialist expertise beyond major medical centers.
At the 40th European Association for Cardio-Thoracic Surgery annual meeting in Barcelona, SS Innovations Chairman and CEO Dr. Sudhir Srivastava remotely performed an atrial septal defect procedure on a patient located in Bengaluru, India. The company also reported that four additional robotic telesurgeries were performed or broadcast during the inaugural Society of Robotic Surgery India conference, covering urological, colorectal, pediatric and gynecological procedures. As of October 23, 2026, SS Innovations reported 205 telesurgeries performed with the SSi Mantra system, including cardiac procedures. The full details of the demonstrations are available in the company’s announcement, which can be accessed through this link.
The implications of these demonstrations are significant for the future of surgical care. Remote robotic surgery could enable hospitals in underserved or rural areas to access specialized surgical expertise without requiring patients or surgeons to travel long distances. This could reduce wait times, lower costs associated with patient transfer, and improve outcomes by allowing timely intervention. However, widespread adoption will depend on several factors, including rigorous clinical validation, reliable connectivity, and regulatory approvals. The company is currently pursuing U.S. Food and Drug Administration clearance for the SSi Mantra, with completion of the 510(k) review targeted for the first quarter of 2027, though the timeline remains subject to the FDA’s review.
For investors and industry observers, the demonstrations position SS Innovations as a player in the emerging tele-surgery market. The company’s progress with the SSi Mantra system and its pursuit of FDA clearance could be key catalysts for future growth. More information about SS Innovations (NASDAQ: SSII) is available through the company’s profile, and ongoing updates can be found in its newsroom at https://ibn.fm/SSII.
The announcements were distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides access to a vast network of wire solutions, including editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution to millions of followers. These services are designed to help companies maximize the impact of their announcements and reach a wide audience of investors, journalists, and the public.
